{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:37:47Z","timestamp":1791221867535,"version":"4.1.0"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Taxane-associated acute pain syndrome (T-APS) is a frequent adverse effect in breast cancer patients undergoing nab-paclitaxel, affecting treatment adherence and quality of life (QoL). We analyzed the effectiveness of preventative celecoxib on T-APS among these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This non-randomized controlled trial included 270 breast cancer patients receiving nab-paclitaxel who experienced musculoskeletal pain during the first cycle. Subjects were assigned to receive celecoxib (200 mg, administered on Days 1\u20137) or a placebo. The main outcome measured was the overall incidence of severe T-APS (&gt;5 on a 0\u201310 scale) during cycles 2\u20134. Secondary endpoints included the incidence, severity, and duration of T-APS (assessed by the Brief Pain Inventory scale); QoL; peripheral nerve function; and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The overall incidence of severe T-APS was 10.2% in the celecoxib group and 50.0% in the placebo group during cycles 2\u20134 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Mean FACT-B subscale scores were significantly higher in the celecoxib group (101.62, 95% CI: 99.70\u2013103.53; 105.59, 95% CI: 103.57\u2013107.61; and 108.02, 95%CI: 106.18\u2013109.85) than the placebo group (99.02, 95% CI: 97.29\u2013100.76; 99.80, 95% CI: 98.03\u2013101.57; and 99.10, 95% CI: 97.39\u2013100.81) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). QoL on EORTC QLQ-C30 was also better in the celecoxib group, except for appetite loss, fatigue, and insomnia (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Following four cycles, the mean scores on the FACT-Ntx subscale in the celecoxib group remained higher (34.10, 95% CI: 33.29\u201334.91 vs 32.25, 95% CI: 31.63\u201332.88) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01). Additionally, the incidence of peripheral neuropathy at grade 1 or higher in CTCAE 5.0 was reduced in the celecoxib group (36.7% vs 63.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Preventative celecoxib significantly reduced the incidence of severe T-APS and improved QoL in breast cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003565","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:03:40Z","timestamp":1759853020000},"page":"614-628","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study"],"prefix":"10.1097","volume":"112","author":[{"given":"Fenmei","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-7156","authenticated-orcid":false,"given":"Guanhua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal (hernia) Surgery, Sanya Central Hospital (Third People\u2019s Hospital of Hainan Province), Sanya, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pangzhou","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Spinal surgery, Foshan Fosun Chancheng Hospital Affiliated to Guangdong Medical University, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-5133","authenticated-orcid":false,"given":"Xinxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"R1-20260518","doi-asserted-by":"crossref","first-page":"2402\u201308","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"283\u2013302","DOI":"10.1016\/j.ctrv.2005.03.007","article-title":"Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review","volume":"31","author":"Trudeau","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R3-20260518","doi-asserted-by":"crossref","first-page":"249\u201356","DOI":"10.1038\/s41591-023-02677-x","article-title":"Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"key":"R4-20260518","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"R5-20260518","doi-asserted-by":"crossref","first-page":"3611\u201319","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab -paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"JCO"},{"key":"R6-20260518","doi-asserted-by":"crossref","first-page":"1705\u201311","DOI":"10.1200\/JCO.2011.39.2613","article-title":"US food and drug administration approval overview in metastatic breast cancer","volume":"30","author":"Cortazar","year":"2012","journal-title":"J Clin Oncol"},{"key":"R7-20260518","first-page":"203\u201311","article-title":"A prospective study of docetaxel-associated pain syndrome","volume":"26","author":"Chiu","year":"2018","journal-title":"Support Care Cancer"},{"key":"R8-20260518","first-page":"3633\u201350","article-title":"Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review","volume":"24","author":"Fernandes","year":"2016","journal-title":"Support Care Cancer"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"56\u201367","DOI":"10.1177\/1078155215627502","article-title":"Taxane-induced arthralgia and myalgia: a literature review","volume":"23","author":"Chiu","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"5171\u201378","DOI":"10.1002\/cncr.27489","article-title":"Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North central cancer treatment group trial N08C1","volume":"118","author":"Reeves","year":"2012","journal-title":"Cancer"},{"key":"R11-20260518","doi-asserted-by":"crossref","first-page":"1472\u201378","DOI":"10.1200\/JCO.2010.33.0308","article-title":"Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1","volume":"29","author":"Loprinzi","year":"2011","journal-title":"JCO"},{"key":"R12-20260518","doi-asserted-by":"crossref","first-page":"150\u201360","DOI":"10.1016\/j.ejca.2022.05.019","article-title":"Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: a phase II randomised trial","volume":"171","author":"Zhang","year":"2022","journal-title":"Eur J Cancer"},{"key":"R13-20260518","first-page":"547\u201353","article-title":"Can pregabalin prevent paclitaxel-associated neuropathy?\u2013An ACCRU pilot trial","volume":"24","author":"Shinde","year":"2016","journal-title":"Support Care Cancer"},{"key":"R14-20260518","first-page":"2673\u201377","article-title":"Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis","volume":"27","author":"Kanbayashi","year":"2019","journal-title":"Support Care Cancer"},{"key":"R15-20260518","first-page":"263\u201376","article-title":"Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons","volume":"25","author":"Benoit","year":"2006","journal-title":"Gen Physiol Biophys"},{"key":"R16-20260518","doi-asserted-by":"crossref","first-page":"1027\u201339","DOI":"10.1038\/sj.bjp.0706407","article-title":"Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels","volume":"146","author":"Webster","year":"2005","journal-title":"Br J Pharmacol"},{"key":"R17-20260518","doi-asserted-by":"crossref","first-page":"244\u201366","DOI":"10.1016\/j.pain.2005.10.035","article-title":"Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome","volume":"120","author":"Albrecht","year":"2006","journal-title":"Pain"},{"key":"R18-20260518","doi-asserted-by":"crossref","first-page":"1\u20139","DOI":"10.1016\/j.tox.2011.10.019","article-title":"Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy","volume":"291","author":"Jaggi","year":"2012","journal-title":"Toxicology"},{"key":"R19-20260518","doi-asserted-by":"crossref","first-page":"1744\u20138069\u20136\u201382","DOI":"10.1186\/1744-8069-6-82","article-title":"Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons","volume":"6","author":"Anand","year":"2010","journal-title":"Mol Pain"},{"key":"R20-20260518","doi-asserted-by":"crossref","first-page":"399\u2013403","DOI":"10.1097\/PPO.0b013e31815a999b","article-title":"The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism","volume":"13","author":"Loprinzi","year":"2007","journal-title":"Cancer J"},{"key":"R21-20260518","doi-asserted-by":"crossref","first-page":"5361\u201372","DOI":"10.1080\/21655979.2021.1955560","article-title":"The protective effects of naproxen against interleukin-1\u03b2 (IL-1\u03b2)- induced damage in human umbilical vein endothelial cells (HUVECs)","volume":"12","author":"Wu","year":"2021","journal-title":"Bioengineered"},{"key":"R22-20260518","doi-asserted-by":"crossref","first-page":"1\u201312","DOI":"10.1155\/2018\/1302835","article-title":"Are all oral COX-2 selective inhibitors the same? A consideration of celecoxib, etoricoxib, and diclofenac","volume":"2018","author":"Walker","year":"2018","journal-title":"Int J Rheumatol"},{"key":"R23-20260518","doi-asserted-by":"crossref","first-page":"3282\u201392","DOI":"10.1093\/eurheartj\/ehx508","article-title":"Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen ambulatory blood pressure measurement) trial","volume":"38","author":"Ruschitzka","year":"2017","journal-title":"Eur Heart J"},{"key":"R24-20260518","doi-asserted-by":"crossref","first-page":"2519\u201329","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"R25-20260518","first-page":"315\u201320","article-title":"The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following Carboplatin and Paclitaxel combination chemotherapy for non-small cell lung cancer","volume":"17","author":"Yoshida","year":"2009","journal-title":"Support Care Cancer"},{"key":"R26-20260518","doi-asserted-by":"crossref","first-page":"676\u201377","DOI":"10.1093\/jnci\/85.8.676","article-title":"Antihistamines in the treatment of taxol-induced paroxystic pain syndrome","volume":"85","author":"Martoni","year":"1993","journal-title":"JNCI J National Cancer Inst"},{"key":"R27-20260518","first-page":"221\u201327","article-title":"Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome","volume":"28","author":"Saito","year":"2020","journal-title":"Support Care Cancer"},{"key":"R28-20260518","doi-asserted-by":"crossref","first-page":"1267\u201376","DOI":"10.1038\/nm.2234","article-title":"Interactions between the immune and nervous systems in pain","volume":"16","author":"Ren","year":"2010","journal-title":"Nat Med"},{"key":"R29-20260518","doi-asserted-by":"crossref","first-page":"57\u201377","DOI":"10.1016\/j.pharmthera.2005.06.003","article-title":"Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms","volume":"109","author":"Ueda","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R30-20260518","first-page":"589\u201398","article-title":"Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study","volume":"28","author":"Asthana","year":"2020","journal-title":"Support Care Cancer"},{"key":"R31-20260518","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13073-023-01193-4","article-title":"Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy","volume":"15","author":"Khan","year":"2023","journal-title":"Genome Med"},{"key":"R32-20260518","doi-asserted-by":"crossref","first-page":"42\u201347","DOI":"10.3747\/co.v17i4.562","article-title":"Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey","volume":"17","author":"Saibil","year":"2010","journal-title":"Current Oncol"},{"key":"R33-20260518","first-page":"168\u201375","article-title":"Measuring quality of life in oncology: is it worthwhile? II. Experiences from the treatment of cancer","volume":"5","author":"Montazeri","year":"1996","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R34-20260518","doi-asserted-by":"crossref","first-page":"e0153714","DOI":"10.1371\/journal.pone.0153714","article-title":"Determinants of quality of life for breast cancer patients in Shanghai, China","volume":"11","author":"Yan","year":"2016","journal-title":"PLoS One"},{"key":"R35-20260518","doi-asserted-by":"crossref","first-page":"1733\u201343","DOI":"10.1007\/s11136-017-1533-5","article-title":"Examining health-related quality of life patterns in women with breast cancer","volume":"26","author":"Pinheiro","year":"2017","journal-title":"Qual Life Res"},{"key":"R36-20260518","first-page":"1452635","article-title":"Health-related quality of life among women breast cancer patients in Eastern China","volume":"2018","author":"Chen","year":"2018","journal-title":"Biomed Res Int"},{"key":"R39-20260518","doi-asserted-by":"crossref","first-page":"1974\u201379","DOI":"10.1200\/JCO.2011.37.8364","article-title":"Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base","volume":"30","author":"Kirshner","year":"2012","journal-title":"J Clin Oncol"},{"key":"R40-20260518","first-page":"2979\u201388","article-title":"Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia?","volume":"24","author":"Chiu","year":"2016","journal-title":"Support Care Cancer"},{"key":"R41-20260518","doi-asserted-by":"crossref","first-page":"908\u201319","DOI":"10.1016\/j.jpainsymman.2018.08.017","article-title":"Phenotypic characterization of paclitaxel-induced peripheral neuropathy in cancer survivors","volume":"56","author":"Kober","year":"2018","journal-title":"J Pain Sympt Manage"},{"key":"R42-20260518","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13104-023-06461-5","article-title":"The humanistic and economic burden of work-related musculoskeletal pain: a cross-sectional survey of workers in the United Kingdom","volume":"16","author":"Smith","year":"2023","journal-title":"BMC Res Notes"},{"key":"R43-20260518","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12955-016-0449-z","article-title":"Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer","volume":"14","author":"Smyth","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"R44-20260518","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R45-20260518","doi-asserted-by":"crossref","first-page":"1108\u201312","DOI":"10.1097\/j.pain.0000000000000890","article-title":"Determination of mild, moderate, and severe pain interference in patients with cancer","volume":"158","author":"Shi","year":"2017","journal-title":"Pain"},{"key":"R46-20260518","doi-asserted-by":"crossref","first-page":"367\u201374","DOI":"10.1002\/mus.21874","article-title":"Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy","volume":"43","author":"Park","year":"2011","journal-title":"Muscle Nerve"},{"key":"R47-20260518","doi-asserted-by":"crossref","first-page":"365\u201376","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R48-20260518","first-page":"148","article-title":"Department of nursing, gazi university school of health sciences, Ankara, Turkey. Symptoms experience and quality of life in the patients with breast cancer receiving the taxane class of drugs","volume":"14","author":"Kirca","journal-title":"Eur J Breast Health"},{"key":"R49-20260518","doi-asserted-by":"crossref","first-page":"101157","DOI":"10.1016\/j.eclinm.2021.101157","article-title":"Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial","volume":"41","author":"Zhou","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R50-20260518","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1097\/EJA.0000000000001546","article-title":"Ultrasound-guided genicular nerves block: an analgesic alternative to local infiltration analgesia for total knee arthroplasty: a noninferiority, matched cohort study","volume":"38","author":"Pietrantoni","year":"2021","journal-title":"Eur J Anaesthesiol"},{"key":"R51-20260518","doi-asserted-by":"crossref","first-page":"150\u201361","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"R52-20260518","first-page":"8059\u201367","article-title":"Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis","volume":"29","author":"Saito","year":"2021","journal-title":"Support Care Cancer"},{"key":"R53-20260518","doi-asserted-by":"crossref","first-page":"187\u201396","DOI":"10.1097\/NCC.0000000000000273","article-title":"State of the science: taxane-induced musculoskeletal pain","volume":"39","author":"Davis","year":"2016","journal-title":"Cancer Nurs"},{"key":"R54-20260518","doi-asserted-by":"crossref","first-page":"268\u201374","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"R55-20260518","doi-asserted-by":"crossref","first-page":"1482\u201394","DOI":"10.1093\/ije\/dyz261","article-title":"Use of E-values for addressing confounding in observational studies\u2014an empirical assessment of the literature","volume":"49","author":"Blum","year":"2020","journal-title":"Int J Epidemiol"},{"key":"R56-20260518","doi-asserted-by":"crossref","first-page":"614\u201325","DOI":"10.1016\/j.ctrv.2014.02.001","article-title":"nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer","volume":"40","author":"Megerdichian","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R57-20260518","first-page":"432\u201344","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"R58-20260518","doi-asserted-by":"crossref","first-page":"1488\u201397","DOI":"10.1016\/S0959-8049(00)00134-9","article-title":"Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist","volume":"36","author":"Kramer","year":"2000","journal-title":"Eur J Cancer"},{"key":"R59-20260518","doi-asserted-by":"crossref","first-page":"235\u201338","DOI":"10.1177\/1049909119864083","article-title":"Loratadine for Paclitaxel-Induced Myalgias and Arthralgias","volume":"37","author":"Smith","year":"2020","journal-title":"Am J Hosp Palliat Care"},{"key":"R60-20260518","first-page":"833\u201338","article-title":"A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome","volume":"25","author":"Jatoi","year":"2017","journal-title":"Support Care Cancer"},{"key":"R61-20260518","doi-asserted-by":"crossref","first-page":"482\u201397","DOI":"10.1002\/glia.23557","article-title":"Interleukin-1beta released by microglia initiates the enhanced glutamatergic activity in the spinal dorsal horn during paclitaxel-associated acute pain syndrome","volume":"67","author":"Yan","year":"2019","journal-title":"Glia"},{"key":"R62-20260518","doi-asserted-by":"crossref","first-page":"15864\u201377","DOI":"10.1021\/acsnano.4c02947","article-title":"Celecoxib augments paclitaxel-induced immunogenic cell death in triple-negative breast cancer","volume":"18","author":"Qian","year":"2024","journal-title":"ACS Nano"},{"key":"R63-20260518","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-27-32","article-title":"Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007","volume":"27","author":"Montazeri","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"R64-20260518","doi-asserted-by":"crossref","first-page":"432\u201338","DOI":"10.1007\/s12032-011-9844-9","article-title":"Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer","volume":"29","author":"Svensson","year":"2012","journal-title":"Med Oncol"},{"key":"R65-20260518","doi-asserted-by":"crossref","first-page":"178\u2013231","DOI":"10.1093\/jnci\/djq508","article-title":"Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009)","volume":"103","author":"Lemieux","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R66-20260518","doi-asserted-by":"crossref","first-page":"858\u201371","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","volume":"22","author":"P\u00e9rez-Garc\u00eda","year":"2021","journal-title":"Lancet Oncol"},{"key":"R67-20260518","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","article-title":"Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"R68-20260518","doi-asserted-by":"crossref","first-page":"47\u201355","DOI":"10.1007\/s10549-023-06867-6","article-title":"Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case-control study","volume":"199","author":"Tsai","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"R69-20260518","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/14737167.4.5.581","article-title":"The truly remarkable universality of half a standard deviation: confirmation through another look","volume":"4","author":"Norman","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R70-20260518","doi-asserted-by":"crossref","first-page":"102\u201309","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"R71-20260518","doi-asserted-by":"crossref","first-page":"5345\u201350","DOI":"10.1200\/JCO.22.02776","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"41","author":"Osoba","year":"2023","journal-title":"J Clin Oncol"},{"key":"R72-20260518","doi-asserted-by":"crossref","first-page":"171\u201382","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"R73-20260518","doi-asserted-by":"crossref","first-page":"898\u2013910","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"R74-20260518","doi-asserted-by":"crossref","first-page":"1713\u201321","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"R75-20260518","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1758-3284-1-26","article-title":"Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy","volume":"1","author":"Epstein","year":"2009","journal-title":"Head Neck Oncol"},{"key":"R76-20260518","first-page":"55\u201362","article-title":"The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer: a randomized trial","volume":"112","author":"Su","year":"2020","journal-title":"J Natl Cancer Inst"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:22:07Z","timestamp":1779110527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003565","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"2025-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}